UA104741C2 - Моноклональні антитіла проти феропортину 1 та варіанти їх застосування - Google Patents

Моноклональні антитіла проти феропортину 1 та варіанти їх застосування

Info

Publication number
UA104741C2
UA104741C2 UAA201107028A UAA201107028A UA104741C2 UA 104741 C2 UA104741 C2 UA 104741C2 UA A201107028 A UAA201107028 A UA A201107028A UA A201107028 A UAA201107028 A UA A201107028A UA 104741 C2 UA104741 C2 UA 104741C2
Authority
UA
Ukraine
Prior art keywords
monoclonal antibodies
ferroportin
maintaining
increasing
iron
Prior art date
Application number
UAA201107028A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Донмайєнн Дон Мун Льюнг
Пен Луань
Джозеф Вінсент Манетта
Їнь Тань
Деррік Райан Уітчер
Original Assignee
Елі Ліллі Енд Компані
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Елі Ліллі Енд Компані filed Critical Елі Ліллі Енд Компані
Publication of UA104741C2 publication Critical patent/UA104741C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA201107028A 2008-12-05 2009-12-01 Моноклональні антитіла проти феропортину 1 та варіанти їх застосування UA104741C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12007608P 2008-12-05 2008-12-05
US23981809P 2009-09-04 2009-09-04
PCT/US2009/066187 WO2010065496A1 (en) 2008-12-05 2009-12-01 Anti-ferroportin 1 monoclonal antibodies and uses thereof

Publications (1)

Publication Number Publication Date
UA104741C2 true UA104741C2 (uk) 2014-03-11

Family

ID=41683589

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201107028A UA104741C2 (uk) 2008-12-05 2009-12-01 Моноклональні антитіла проти феропортину 1 та варіанти їх застосування

Country Status (25)

Country Link
EP (1) EP2373335B1 (https=)
JP (1) JP5713917B2 (https=)
KR (1) KR101353117B1 (https=)
CN (1) CN102238962B (https=)
AR (1) AR074398A1 (https=)
AU (1) AU2009322587B2 (https=)
BR (1) BRPI0922288A2 (https=)
CA (1) CA2745618C (https=)
CY (1) CY1117355T1 (https=)
DK (1) DK2373335T3 (https=)
EA (1) EA020472B1 (https=)
ES (1) ES2566343T3 (https=)
HR (1) HRP20160302T1 (https=)
HU (1) HUE028585T2 (https=)
IL (1) IL212731A0 (https=)
MX (1) MX2011005939A (https=)
NZ (1) NZ592545A (https=)
PA (1) PA8849601A1 (https=)
PL (1) PL2373335T3 (https=)
SG (1) SG171960A1 (https=)
SI (1) SI2373335T1 (https=)
TW (1) TW201023891A (https=)
UA (1) UA104741C2 (https=)
WO (1) WO2010065496A1 (https=)
ZA (1) ZA201103941B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2871116A1 (en) * 2012-05-14 2013-11-21 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US12263205B2 (en) 2018-04-30 2025-04-01 The Children's Hospital Of Philadelphia Methods of improving anemias by combining agents
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
CN110806486B (zh) * 2019-11-23 2023-03-21 中南大学湘雅三医院 Mafg/as1/pcbp2/fpn1调控轴作为靶位点检测试剂的应用
WO2021231798A1 (en) 2020-05-13 2021-11-18 Disc Medicine, Inc. Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CN113980987A (zh) * 2021-12-06 2022-01-28 上海市农业科学院 一种提高植物抗镍性能的PgIREG1S和AlATP-PRTS双基因组及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166448B1 (en) * 1999-05-10 2007-01-23 Children's Medical Center Corproation Ferroportin1 nucleic acids and proteins
IT1319221B1 (it) * 2000-10-17 2003-09-26 Antonello Pietrangelo Mutazioni nel gene della ferroportina 1 associata ad emocromatosiereditaria.
ES2500066T3 (es) * 2008-01-25 2014-09-30 Amgen, Inc Anticuerpos frente a ferroportina y métodos de uso

Also Published As

Publication number Publication date
CA2745618C (en) 2014-06-10
AR074398A1 (es) 2011-01-12
SI2373335T1 (sl) 2016-04-29
ZA201103941B (en) 2012-11-28
CN102238962B (zh) 2014-02-12
EP2373335A1 (en) 2011-10-12
KR101353117B1 (ko) 2014-02-17
JP5713917B2 (ja) 2015-05-07
BRPI0922288A2 (pt) 2018-08-28
SG171960A1 (en) 2011-07-28
DK2373335T3 (en) 2016-05-02
TW201023891A (en) 2010-07-01
CN102238962A (zh) 2011-11-09
NZ592545A (en) 2012-12-21
EA020472B1 (ru) 2014-11-28
HUE028585T2 (en) 2016-12-28
CA2745618A1 (en) 2010-06-10
HRP20160302T1 (hr) 2016-04-22
AU2009322587A1 (en) 2011-07-28
EA201170764A1 (ru) 2011-12-30
JP2012510814A (ja) 2012-05-17
KR20110084996A (ko) 2011-07-26
MX2011005939A (es) 2011-06-27
ES2566343T3 (es) 2016-04-12
HK1158977A1 (zh) 2012-07-27
PA8849601A1 (es) 2010-07-27
WO2010065496A1 (en) 2010-06-10
IL212731A0 (en) 2011-07-31
AU2009322587B2 (en) 2013-09-26
CY1117355T1 (el) 2017-04-26
PL2373335T3 (pl) 2016-08-31
EP2373335B1 (en) 2016-02-24

Similar Documents

Publication Publication Date Title
JO2828B1 (en) Anti-Hepsidine antibodies and their uses
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
UA104741C2 (uk) Моноклональні антитіла проти феропортину 1 та варіанти їх застосування
WO2011126833A3 (en) Anti-inflammatory factors
EA202091230A3 (ru) Антагонисты активин-actrii и их применения для повышения уровней эритроцитов
MA32190B1 (fr) Anticorps dirigés contre l'angiopoïétine 1 et l'angiopoïétine 2 et leur utilisation
PH12013500826A1 (en) Means and methods for treating dlbcl
WO2005123779A3 (en) Antibodies binding to cd34+/cd36+ fetal but not to adult cells
EA201170312A1 (ru) Селективные антитела к гепцидину-25 и их применение
RU2599417C3 (ru) Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
HK1199837A1 (en) Humanized antibodies to inkt
WO2013136189A3 (en) Methods and materials for treatment of pompe's disease
UA105760C2 (uk) Антитіло проти bst2
NZ609567A (en) Markers of endothelial progenitor cells and uses thereof
SG171674A1 (en) Methods of treating cancer by administering human il-18 combinations
WO2017160699A3 (en) Method of preventing graft versus host disease
WO2008135960A3 (en) A composition for increasing stamina
WO2012022734A3 (en) Anti-icam-1 antibodies and methods of use
MX2023001937A (es) Anticuerpos monoclonales, composiciones y métodos para detectar el factor d del complemento.
HK1200355A1 (en) Treatment of red blood cells
WO2009022988A3 (en) Vhz for diagnosis and treatment of cancer
Abou Ayache et al. Preemptive renal transplantation in adults
WO2007005502A3 (en) Methods and compositions for treating diseases targeting cdcp1
WO2013071038A3 (en) Antagonists for abnormal vasopressin v2 receptor and uses thereof